WASHINGTON, Jan 16 (Reuters) - The U.S. Supreme Court agreed on Friday to hear a patent dispute involving Amarin Pharma's cardiovascular drug Vascepa that could have broad consequences for generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results